CB 1954: From the Walker Tumor to NQO2 and VDEPT

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|26|2091-2104

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.26, 2003-10, pp. : 2091-2104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CB2 Receptor Ligands

By  

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 7, 2005-07 ,pp. : 641-649

Bentham Science Publishers

Access to resources Recommend Favorite

CB Receptor Ligands from Plants

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 3, 2008-02 ,pp. : 173-186

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands

By  

Current Medicinal Chemistry, Vol. 21, Iss. 2, 2014-01 ,pp. : 187-203

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists

By  

Current Medicinal Chemistry, Vol. 15, Iss. 14, 2008-06 ,pp. : 1428-1443

Bentham Science Publishers

Access to resources Recommend Favorite

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB 1 /CB 2 receptors

By Brooks J.W.   Pryce G.   Bisogno T.   Jaggar S.I.   Hankey D.J.R.   Brown P.   Bridges D.   Ledent C.   Bifulco M.   Rice A.S.C.   Di Marzo V.   Baker D.  

European Journal of Pharmacology, Vol. 439, Iss. 1, 2002-03 ,pp. : 83-92

Elsevier

Access to resources Recommend Favorite